Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

22.08.24	Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine (Businesswire)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
16.08.24	Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine (RTTNews)
16.08.24	Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age (Businesswire)
12.08.24	Pfizer's RSV Vaccine ABRYSVO Shows Positive Results In Phase 3 Study In Immunocompromised Adults (RTTNews)
12.08.24	Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults (Businesswire)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
31.07.24	ViiV Healthcare Reports Positive Data For 2-Drug Regimen DOVATO In HIV-1 Treatment (RTTNews)
30.07.24	Pfizer Boost FY24 Outlook - Update (RTTNews)
30.07.24	Pfizer Inc. Q2 Profit Decreases, But Beats Estimates (RTTNews)
30.07.24	Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
25.07.24	Pfizer Gets EC's Conditional Authorization For Durveqtix Genetherapy In Hemophilia B (RTTNews)
25.07.24	European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.07.24	Pfizer's Phase 3 AFFINE Study Of Hemophilia A Gene Therapy Candidate Meets Primary Goal (RTTNews)
24.07.24	Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate (Businesswire)
11.07.24	Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron (RTTNews)
11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer Chief Scientific Officer Mikael Dolsten To Step Down (RTTNews)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
03.07.24	GSK Acquires Global Rights For MRNA Vaccines For Influenza & COVID-19 In CureVac Deal - Quick Facts (RTTNews)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer, BioNTech Get CHMP's Positive Opinion For Marketing Authorization Of Omicron JN.1 Vaccine (RTTNews)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
13.06.24	Pfizer's Phase 3 Duchenne Gene Therapy Trial Fails To Meet Primary And Secondary Endpoints (RTTNews)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer's Phase 3 Crown Trial Of Lobrena Reports 5-year Non-progression Results In NSCLC Patients (RTTNews)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
23.05.24	Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units (RTTNews)
16.05.24	Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib (RTTNews)
13.05.24	Amazon, Microsoft, Pfizer To Invest Billions In French Projects (RTTNews)
06.05.24	Andrew Baum To Oversee Pfizer's Innovation, Portfolio Strategy (RTTNews)
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)
01.05.24	Pfizer Boost FY24 Adj. EPS Outlook - Update (RTTNews)
01.05.24	Pfizer Inc. Q1 Profit Decreases, but beats estimates (RTTNews)
01.05.24	Pfizer Reports First-Quarter 2024 Results (Businesswire)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
30.04.24	Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer (RTTNews)
30.04.24	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer (Businesswire)
29.04.24	Labcorp: FDA Approves NAbCyte Companion Diagnostic - Quick Facts (RTTNews)
29.04.24	Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting (Businesswire)
26.04.24	Pfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B (RTTNews)
26.04.24	U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.04.24	Pfizer Declares Second-Quarter 2024 Dividend (Businesswire)
22.04.24	Pfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease (RTTNews)
22.04.24	European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

17:57		Börse Europa in Grün: STOXX 50 steigt schlussendlich
17:57		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
17:57		Dienstagshandel in London: Letztendlich Gewinne im FTSE 100
16:15		AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück
16:02		Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor einem Jahr eingefahren
16:02		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr eingebracht
16:00		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen

17:57

Börse Europa in Grün: STOXX 50 steigt schlussendlich

17:57

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50

17:57

Dienstagshandel in London: Letztendlich Gewinne im FTSE 100

16:15

AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück

16:02

Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor einem Jahr eingefahren

16:02

S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr eingebracht